Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Mira1a Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/14/2023 |
SC 13D
| Bay Shore Trust reports a 23.9% stake in MIRA PHARMACEUTICALS, INC. |
| 08/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"UNDERWRITING AGREEMENT between MIRA PHARMACEUTICALS, INC. and KINGSWOOD INVESTMENTS, division of Kingswood Capital Partners, LLC, as Representative of the Several Underwriters UNDERWRITING AGREEMENT between MIRA PHARMACEUTICALS, INC. and KINGSWOOD INVESTMENTS, division of Kingswood Capital Partners, LLC, as Representative of the Several Underwriters New York, New York August 2, 2023 Kingswood Investments, division of Kingswood Capital Partners, LLC as Representative of the several Underwriters named on Schedule 1 hereto 17 Battery Place, Suite 625 New York, New York 10004",
"Representative’ s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE TO ANYONE OTHER THAN KINGSWOOD INVESTMENTS, DIVISION OF KINGSWOOD CAPITAL PARTNERS, LLC OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR A BONA FIDE OFFICER OR PARTNER OF KINGSWOOD INVESTMENTS, DIVISION OF KINGSWOOD CAPITAL PARTNERS, LLC OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER. THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO FEBRUARY 2, 2024. VOI...",
"MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing",
"MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering" |
|
| 08/04/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/04/2023 |
424B1
| Form 424B1 - Prospectus [Rule 424(b)(1)]: |
| 08/03/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/31/2023 |
CERT
| Form CERT - Certification by an exchange approving securities for listing: |
| 07/31/2023 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 07/28/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/25/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/21/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/18/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/14/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 06/29/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 08/01/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/01/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
|
|